Cat’s Claw / GSH Cancer Research Results

Cats, Cat’s Claw: Click to Expand ⟱
Features:
Cat’s Claw (Uncaria tomentosa) – Known for its immune-boosting properties.
Dose: Tea 1-2g, 1-3x/d. Extract 250-500mg/d

Cat’s Claw — usually refers to extracts of Uncaria tomentosa bark, a South American medicinal vine used as a botanical mixture rather than a single defined molecule. It is best classified as a phytotherapeutic natural-product extract with immunomodulatory, anti-inflammatory, and context-dependent cytotoxic activity. Common abbreviations include UT and, less specifically, cat’s claw. Major constituent classes include pentacyclic oxindole alkaloids, tetracyclic oxindole alkaloids, proanthocyanidins, quinovic acid glycosides, and related polyphenols/triterpenes. In oncology, the main issue is heterogeneity: chemotype, extraction solvent, and alkaloid/proanthocyanidin composition can shift the dominant biology, so “Cat’s Claw” should not be treated as a pharmacologically uniform agent.

Primary mechanisms (ranked):

  1. Immune-inflammatory signaling modulation centered on TNF-α / NF-κB suppression
  2. Intrinsic apoptosis induction in susceptible cancer cells via mitochondrial signaling, cytochrome c release, caspase activation, Bax↑ and anti-apoptotic Bcl-family restraint↓
  3. Redox modulation with context-dependent ROS effects; antioxidant/cytoprotective activity in inflammatory or normal-cell settings, but pro-oxidant stress can contribute to cancer-cell killing in some models
  4. MAPK-pathway modulation and downstream cytokine reprogramming
  5. Adjunctive chemotherapy interaction biology, including reported enhancement of treatment-induced apoptosis or differential protection of normal vs malignant cells in some preclinical systems
  6. Transporter / drug-metabolism interaction potential, relevant to clinical translation more than to direct anticancer effect

Bioavailability / PK relevance: Human PK is not well standardized because Cat’s Claw is a multicomponent extract and marketed products vary widely. Standardization usually focuses on pentacyclic oxindole alkaloids, but different fractions can behave differently and mixed chemotypes may not be therapeutically equivalent. Practical translation is therefore constrained more by extract identity and interaction liability than by a clean single-agent PK model.

In-vitro vs systemic exposure relevance: Much of the direct anticancer literature uses crude extracts or fraction concentrations that are difficult to map to reproducible systemic exposure in humans. That makes the anti-inflammatory and supportive-care signals more clinically grounded than claims of reliable direct tumor cytotoxicity. Concentration-response findings should therefore be interpreted as extract-specific and often preclinical rather than as evidence of achievable human tumor exposure.

Clinical evidence status: Small human adjunct/supportive-care evidence exists, but there is no convincing clinical evidence that Cat’s Claw produces objective anticancer responses as a stand-alone treatment. Randomized/controlled oncology data are limited to supportive-care settings, with one breast-cancer adjuvant study reporting reduced chemotherapy-associated neutropenia/DNA damage and a colorectal-cancer trial showing no clear benefit on measured chemotherapy side effects; a phase II advanced-solid-tumor study suggested quality-of-life and fatigue improvement without objective tumor responses.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 TNF-α / NF-κB inflammatory transcription ↓ TNF-α signaling; ↓ NF-κB-dependent survival/inflammatory tone (model-dependent) ↓ inflammatory activation and cytokine stress R-G Anti-inflammatory reprogramming Most reproducible cross-model axis; likely central for supportive-care rationale and some indirect anticancer effects.
2 Mitochondrial apoptosis Bax ↑; Bcl-xL/Bcl-2 restraint ↓; cytochrome c release ↑; caspases ↑; apoptosis ↑ Usually limited direct toxicity at tested supportive doses, but extract-dependent R-G Direct tumor-cell killing Strongest direct anticancer signal is in leukemia and selected solid-tumor models; activity depends heavily on fraction/chemotype.
3 ROS balance ROS ↑ in some cancer models; in other systems oxidative damage/lipid peroxidation ↓ ROS stress ↓ and cytoprotection ↑ are commonly reported P-R Context-dependent redox control Cat’s Claw is not a simple pro-oxidant or antioxidant. Cancer-cell apoptosis can be ROS-linked, whereas normal/inflammatory settings often show antioxidant behavior.
4 MAPK signaling MAPK signaling ↓ with altered cytokine program Inflammatory MAPK tone ↓ R Cytokine and survival-pathway modulation Supports the TNF-α / NF-κB story rather than standing fully separate from it.
5 DNA damage response / leukocyte recovery No established direct antitumor DDR mechanism DNA repair capacity / leukocyte recovery ↑ (reported in adjunct settings) G Host-supportive adjunct effect Clinically relevant because the best human oncology signals are supportive rather than tumoricidal.
6 Chemosensitization / differential normal-cell protection Apoptosis with chemotherapy ↑ in some models; cisplatin sensitivity may ↑ Normal-cell oxidative injury may ↓ in some models G Adjunct treatment modulation Potentially useful but still preclinical and extract-specific; dual cancer-sensitizing plus normal-tissue-protective framing is not yet clinically secure.
7 Drug transporters and metabolism May alter exposure to co-administered anticancer drugs indirectly Same G Interaction liability Reported CYP3A4/PXR/transporter effects make combination use clinically important even though this is not a tumor-targeting mechanism.
8 Clinical Translation Constraint Direct anticancer efficacy uncertain Tolerability generally acceptable short term G Standardization and trial limitation Major constraint is product heterogeneity: bark vs leaf, aqueous vs ethanolic, POA-rich vs PAC-rich, and mixed chemotypes can produce materially different biology.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.
Scientific Papers found: Click to Expand⟱
5919- Cats,  Cisplatin,    Uncaria tomentosa Leaves Decoction Modulates Differently ROS Production in Cancer and Normal Cells, and Effects Cisplatin Cytotoxicity
- in-vitro, Liver, HepG2
ROS↑, GSH↓, Apoptosis↑, Casp3↑, Casp7↑, NF-kB↓, selectivity↑, ChemoSen↑, chemoP↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp3↑, 1,   Casp7↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GSH, Glutathione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:221  Target#:137  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page